Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Total Current Liabilities (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Total Current Liabilities for 16 consecutive years, with $170.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 1.1% year-over-year to $170.5 million, compared with a TTM value of $170.5 million through Dec 2025, up 1.1%, and an annual FY2025 reading of $170.5 million, up 1.1% over the prior year.
  • Total Current Liabilities was $170.5 million for Q4 2025 at Orthofix Medical, up from $159.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $170.5 million in Q4 2025 and bottomed at $77.6 million in Q3 2022.
  • Average Total Current Liabilities over 5 years is $127.7 million, with a median of $143.0 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities fell 20.98% in 2022, then soared 97.58% in 2023.
  • Year by year, Total Current Liabilities stood at $105.8 million in 2021, then dropped by 20.98% to $83.6 million in 2022, then skyrocketed by 97.58% to $165.2 million in 2023, then rose by 2.06% to $168.6 million in 2024, then grew by 1.1% to $170.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for OFIX at $170.5 million in Q4 2025, $159.8 million in Q3 2025, and $148.4 million in Q2 2025.